Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation

Trial ID or NCT#

NCT00185757

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of the study is to determine if the use of activated T cells can effectively treat relapsed disease following allogeneic hematopoietic cell transplantation without causing GVHD.

Official Title

Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation

Eligibility Criteria

Ages Eligible for Study: 18 Years to 75 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Evidence of recurrent or persistent hematologic malignancy following HLA matched allogeneic hematopoietic cell transplant - eligible for DLI - no evidence of GVHD - stable immunosuppressive regimen - adequate renal and liver function
Exclusion Criteria:
  1. - CML patients who have not received DLI, active infections
View All Criteria
Show Less

Investigator(s)

Robert Negrin
Robert Negrin
Blood and marrow transplant specialist, Hematologist, Blood and marrow transplant specialist
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Contact us to find out if this trial is right for you.

Contact

BMT Referrals
6507230822

View on ClinicalTrials.gov